Table 3.
Disease activity and function before and after weight loss treatment in 41 patients with PsA
| Baseline Median (IQR) Min–max |
6 months Median (IQR) Min–max |
p value | |
|---|---|---|---|
| Weight, kg | 106.3 (95.8–113.6) 84–124 |
82.9 (76.4–92.1) 61.3–107.4 |
< 0.001 |
| BMI, kg/m2 | 35.2 (34.1–38.1) 33.0–45.8 |
29.8 (26.6–31.5) 23.1–37.0 |
< 0.001 |
| Waist circumference, cm | 116 (112–122) 103–135 |
95.5 (89–103) 81–116 |
< 0.001 |
| CRP, mg/L | 4 (2–8.5) 1–50 |
2 (1–6.5) 1–50 |
0.041 |
| Hemoglobin, g/L | 144 (132–150) 116–179 |
141 (131.5–148) 118–161 |
0.047 |
| WBC, 109/L | 5.9 (5.2–7.6) 4.3–15.2 |
5.9 (5.0–6.8) (3.2–12.7) |
0.062 |
| PLT, 109/L | 270 (204–300) 174–444 |
230 (186–290) 156–402 |
< 0.001 |
| Tender joints 68, score | 4 (1–14) 0–30 |
2 (0–6.5) 0–19 |
< 0.001 |
| Swollen joints 66, score | 0 (0–1) 0–5 |
0 (0–0.5) 0–7 |
0.021 |
| VAS patients global disease activity, mm | 34 (19–61) 0–93 |
12 (5–51) 0–95 |
0.001 |
| VAS pain, mm | 30 (18.5–62.5) 0–95 |
20 (5–51.5) 0–95 |
0.004 |
| VAS fatigue, mm | 56 (21.5–67) 0–94 |
25 (8–44) 0–98 |
0.001 |
| DAS28CRP, score | 2.9 (2.1–3.7) 1.4–5.6 |
2.4 (1.7–3.0) 1.2–4.5 |
< 0.001 |
| DAPSA, score | 15.3 (6.6–29.1) 0.9–46 |
11.0 (2.8–17.6) 0.2–35 |
< 0.001 |
| Leeds enthesitis index | 1 (0–4) 0–6 |
0 (0–3) 0–4 |
0.001 |
| BSA, % | 1.6 (0–2.2) 0–10 |
0.9 (0–1.1) 0–5.5 |
0.014 |
| HAQ, score | 0.70 (0.13–1.00) 0–2.63 |
0.43 (0–0.69) 0–1.88 |
< 0.001 |
| DLQI, score | 1 (0–4.5) 0–17 |
1 (0–4) 0–20 |
0.453 |
BMI body mass index, BSA body surface area, CRP C-reactive protein, DAPSA Disease Activity in PSoriatic Arthritis, DAS28CRP Disease Activity Score using 28 joint counts based on CRP, DLQI Dermatology Life Quality Index, PLT platelet count, WBC white blood cell count